| __timestamp | Alnylam Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 461543000 |
| Thursday, January 1, 2015 | 276495000 | 634806000 |
| Friday, January 1, 2016 | 382392000 | 661905000 |
| Sunday, January 1, 2017 | 390635000 | 610753000 |
| Monday, January 1, 2018 | 505420000 | 696328000 |
| Tuesday, January 1, 2019 | 655114000 | 715007000 |
| Wednesday, January 1, 2020 | 654819000 | 628116000 |
| Friday, January 1, 2021 | 792156000 | 628793000 |
| Saturday, January 1, 2022 | 883015000 | 649606000 |
| Sunday, January 1, 2023 | 1004415000 | 746773000 |
| Monday, January 1, 2024 | 1126232000 | 747184000 |
Unleashing the power of data
In the competitive landscape of biopharmaceuticals, innovation is key. Over the past decade, Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. have been at the forefront of research and development (R&D) spending. From 2014 to 2023, Alnylam's R&D expenses surged by over 400%, peaking at approximately $1 billion in 2023. This reflects their commitment to pioneering RNA interference therapeutics. Meanwhile, BioMarin's R&D investment grew by about 60%, reaching nearly $750 million in the same year, underscoring their focus on rare genetic diseases.
This trend highlights a broader industry shift towards increased R&D spending, driven by the need for innovative treatments. As these companies continue to invest heavily in research, they not only advance their own pipelines but also set a benchmark for the industry, emphasizing the critical role of sustained innovation in achieving long-term success.
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc.
GSK plc vs Alnylam Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. vs Madrigal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Grifols, S.A.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs MiMedx Group, Inc.
Research and Development Investment: BioMarin Pharmaceutical Inc. vs Jazz Pharmaceuticals plc
Research and Development: Comparing Key Metrics for BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs CRISPR Therapeutics AG
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Celldex Therapeutics, Inc.